AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’

AbbVie is going heavy on repetition with the first series of ads for its new preventative migraine drug, Qulipta.

The drug, an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), was FDA-approved late last year to prevent episodic migraine and launched around three months ago.